Northwest Biotherapeutics (NWBO) FCF Margin (2010 - 2026)
Northwest Biotherapeutics (NWBO) posted quarterly FCF Margin of 2558.3% for Q1 2026, down 2203.0% year-over-year from 121.65% in Q1 2025, and down 9.72% quarter-over-quarter from 2331.7% in Q4 2025.
Powered by 
Analysis
Northwest Biotherapeutics (NWBO) FCF Margin (2010 - 2026) Analysis & Trends
Northwest Biotherapeutics' FCF Margin history runs 17 years deep, the most recent figure standing at 2558.3% for Q1 2026.
- In Q1 2026, FCF Margin fell 2203.0% year-over-year to 2558.3%; the TTM figure through Mar 2026 stood at 3299.53% (up 42735.0% YoY), while the FY2025 annual figure was 3357.55%, up 84151.0% from the prior year.
- FCF Margin for Q1 2026 stood at 2558.3%, down from 2331.7% in the prior quarter.
- The five-year high for FCF Margin was 1428.64% in Q1 2023, with the low at 8770.13% in Q4 2024.
- The 5-year median for FCF Margin is 3278.04% (2024), against an average of 4124.76%.
- The sharpest annual moves came in 2022 and 2025: FCF Margin slumped 518568 bps in 2022, then surged 643843 bps in 2025.
- Northwest Biotherapeutics' FCF Margin stood at 1844.05% in 2022, then tumbled by 112 bps to 3904.72% in 2023, then sank by 125 bps to 8770.13% in 2024, then jumped by 73 bps to 2331.7% in 2025, then slipped by 10 bps to 2558.3% in 2026.
- Business Quant data shows NWBO's FCF Margin at 2558.3% in Q1 2026, 2331.7% in Q4 2025, and 7047.5% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | Northwest Biotherapeutics | 278.23 Mn | 277.63 Mn | - | -912.89% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -912.89% |
| Mar 31, 2026 | -2,558.30% |
| Dec 31, 2025 | -2,331.70% |
| Sep 30, 2025 | -7,047.50% |
| Jun 30, 2025 | -5,337.40% |
| Mar 31, 2025 | -2,536.27% |
| Dec 31, 2024 | -8,770.13% |
| Sep 30, 2024 | -2,355.46% |
| Jun 30, 2024 | -3,278.04% |
| Mar 31, 2024 | -4,452.46% |
| Dec 31, 2023 | -3,904.72% |
| Sep 30, 2023 | -3,535.96% |
| Jun 30, 2023 | -6,353.23% |
| Mar 31, 2023 | -1,428.64% |
| Dec 31, 2022 | -1,844.05% |
| Sep 30, 2022 | -7,958.25% |
| Jun 30, 2022 | -3,196.86% |
| Mar 31, 2022 | -3,232.01% |
| Sep 30, 2021 | -2,772.57% |
| Jun 30, 2021 | -1,994.95% |